A Meta-Analysis On The Efficacy And Safety Of 1% Lauromacrogol For The Treatment Of Hemangiomas And Vascular Malformations

Objective:The objective of the study is to investigate the efficacy and safety of 1% lauromacrogol to clarify the curative effect of 1% lauromacrogol sclerotherapy on hemangiomas and vascular malformations. Also,the study will put forward evidence-based medical evidence for clinical rational drug therapy.Methods:The Cochrane systematic review was carried out by searching Pubmed(building-2014.12), the Cochrane(building-2014.12), Science Direct( SDOS)(building-2014.12), China Academic Journal CKNI(1979-2014.12), VIP Database for Chinese Technical Periodicals(1989-2014.12), Chinese Biomedical Literature Database CBM(1978-2013.03), Wanfang database(1998-2014.12). The Clinical Randomized Controlled trials(RCTs) that analyzed the efficacy and safety of 1% lauromacrogol sclerotherapy on hemangiomas and vascular malformations were brought in. The software named rev Man 5.2 was used to review these dates. The rate of efficacy and untoward efficacy was calculated and then we carried on statistical analysis by input these data into rev Man 5.2. The outcome was indicated by odds ratio(OR) with it’s 95% confidence intervals(CI). The publication bias was showed by funnel plot.Results:19 studies, amount to 1768 patients were included for this meta-analysis finally. The efficacie of 1% lauromacrogol and ethyl alcohol in hemangiomas and vascular malformations treatment have no statistical differences(OR=0.34,95% CI:0.05-2.30,P=0.27)while the rates of adverse effects(OR=0.46,95% CI:0.22-0.96,P=0.04) have statistical difference. As well, the efficacies of lauromacrogol and pingyangmycin in hemangiomas and VMs treatment have no statistical difference(OR=0.92,95% CI:0.39-2.16,P=0.85). And the rates of adverse effects of lauromacrogol is lower than the latter(OR=0.20,95% CI:0.07-0.58,P=0.003). The effective rate(OR=2.01,95% CI:0.85-4.75,P=0.11)of 1% lauromacrogol and interventional therapy in hemangiomas and vascular malformations treatment have no statistical difference and the adverse effects rate is lower(OR=0.29,95% CI:0.09-0.97,P=0.04). The effective rate(OR=2.65,95% CI:0.85-8.31,P=0.09)and the adverse effects rate(OR=0.88,95% CI:0.14-5.57,P=0.89)of lauromacrogol also have no statistical differences compared with interventional therapy. The efficacies(OR=1.49,95% CI:0.12-18.68,P=0.76)and adverse effects(OR=1.30,95% CI:0.08-21.90,P=0.86) of lauromacrogol and ethanolamine have no statistical differences. The efficacies(RR=1.84,95% CI:1.25-2.72,P=0.002)have statistical differences and the adverse effects(OR=0.35,95% CI:0.10-1.19,P=0.09)of lauromacrogol foam and liquid have no statistical differences. The efficacies(OR=0.47,95% CI:0.25-0.88,P=0.02)and the adverse effects(OR=0.46,95% CI:0.22-0.96,P=0.04)of 1% and 3% lauromacrogol both have statistical difference.Conclusion:The outcome of this study indicates that 1% lauromacrogol sclerotherapy on hemangiomas and VMs has no significant advantages compared with other treatments. However, the rates of adverse reactions seem quite lower than the latters. As a result, lauromacrogol sclerotherapy is a safe and effective treatment.